138 related articles for article (PubMed ID: 34493466)
1. Precision sampling fuels precision oncology: an evolutionary perspective.
Manini C; López-Fernández E; López JI
Trends Cancer; 2021 Nov; 7(11):978-981. PubMed ID: 34493466
[TBL] [Abstract][Full Text] [Related]
2. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
3. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology.
Sanfrancesco JM; Cheng L
Crit Rev Oncol Hematol; 2017 Nov; 119():23-28. PubMed ID: 29065981
[TBL] [Abstract][Full Text] [Related]
4. Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.
Manini C; López-Fernández E; López JI
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884442
[TBL] [Abstract][Full Text] [Related]
5. Convergent insights into intratumor heterogeneity.
Manini C; Laruelle A; Rocha A; López JI
Trends Cancer; 2024 Jan; 10(1):12-14. PubMed ID: 37684129
[TBL] [Abstract][Full Text] [Related]
6. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin R; Lahrmann B; Warsow G; Hübschmann D; Spath C; Walter B; Chen X; Hofer L; Macher-Goeppinger S; Tolstov Y; Korzeniewski N; Duensing A; Grüllich C; Jäger D; Perner S; Schönberg G; Nyarangi-Dix J; Isaac S; Hatiboglu G; Teber D; Hadaschik B; Pahernik S; Roth W; Eils R; Schlesner M; Sültmann H; Hohenfellner M; Grabe N; Duensing S
Nat Commun; 2016 Jun; 7():ncomms11845. PubMed ID: 27291893
[TBL] [Abstract][Full Text] [Related]
7. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
[TBL] [Abstract][Full Text] [Related]
8. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
9. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
10. Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.
Miheecheva N; Postovalova E; Lyu Y; Ramachandran A; Bagaev A; Svekolkin V; Galkin I; Zyrin V; Maximov V; Lozinsky Y; Isaev S; Ovcharov P; Shamsutdinova D; Cheng EH; Nomie K; Brown JH; Tsiper M; Ataullakhanov R; Fowler N; Hsieh JJ
Cell Rep; 2022 Aug; 40(7):111180. PubMed ID: 35977503
[TBL] [Abstract][Full Text] [Related]
11. Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.
López JI; Angulo JC
Curr Urol Rep; 2018 Jan; 19(1):3. PubMed ID: 29374850
[TBL] [Abstract][Full Text] [Related]
12. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
[TBL] [Abstract][Full Text] [Related]
13. A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma.
Lopez JI; Cortes JM
F1000Res; 2016; 5():385. PubMed ID: 27127618
[TBL] [Abstract][Full Text] [Related]
14. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.
Guarch R; Lawrie CH; Larrinaga G; Angulo JC; Pulido R; López JI
Ann Diagn Pathol; 2018 Jun; 34():27-30. PubMed ID: 29661723
[TBL] [Abstract][Full Text] [Related]
15. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
Lobo NC; Gedye C; Apostoli AJ; Brown KR; Paterson J; Stickle N; Robinette M; Fleshner N; Hamilton RJ; Kulkarni G; Zlotta A; Evans A; Finelli A; Moffat J; Jewett MA; Ailles L
BMC Cancer; 2016 Jul; 16():485. PubMed ID: 27422173
[TBL] [Abstract][Full Text] [Related]
16. Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.
Udayakumar D; Zhang Z; Xi Y; Dwivedi DK; Fulkerson M; Haldeman S; McKenzie T; Yousuf Q; Joyce A; Hajibeigi A; Notgrass H; de Leon AD; Yuan Q; Lewis MA; Madhuranthakam AJ; Sibley RC; Elias R; Guo J; Christie A; McKay RM; Cadeddu JA; Bagrodia A; Margulis V; Brugarolas J; Wang T; Kapur P; Pedrosa I
Clin Cancer Res; 2021 Sep; 27(17):4794-4806. PubMed ID: 34210685
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling.
López-Fernández E; López JI
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518081
[TBL] [Abstract][Full Text] [Related]
18. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
19. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Tannock IF
Eur Urol; 2014 Apr; 65(4):846-7. PubMed ID: 24559903
[No Abstract] [Full Text] [Related]
20. Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm.
Pallikonda HA; Turajlic S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188759. PubMed ID: 35835341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]